HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Goetz, C. G. Search for Related Content PubMed PubMed Citation Articles by Goetz, C. G.

Highlights of the North American and European experiences

From Rush University/Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.

Address correspondence and reprint requests to Dr. Christopher G. Goetz, Department of Neurological Sciences, Rush University/Rush-Presbyterian St. Luke's Medical Center, 1725 W. Harrison Street, Chicago, IL 60612.

Abstract.

Two large, randomized, double-blind, placebo-controlled multicenter studies, one North American and one European, examined the efficacy and safety of 300 and 600 mg/day tolcapone in similar populations of patients (n= 379) with Parkinson's disease currently taking levodopa and experiencing motor fluctuations. Change in "on-off" function was the most important end-point assessment. The two studies found similar results. The percentage of "on" time improved significantly and "off" time was reduced. Daily levodopa dosage requirements decreased significantly. The most common and significant adverse event was increased dyskinesia; hallucinations were not frequently encountered.